OTCM
BTCY
Market cap11mUSD
Jun 13, Last price
0.52USD
1D
-6.20%
1Q
-6.42%
Jan 2017
-96.97%
IPO
-97.05%
Name
Biotricity Inc
Chart & Performance
P/E
—
P/S
1.07
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.08%
Rev. gr., 5y
97.82%
Revenues
12m
+25.15%
Net income
-14m
L-24.46%
CFO
-7m
L-50.59%
Earnings
Jun 25, 2025
Profile
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2015‑12 | 2015‑08 | |
| Income | ||||||||||
Revenues | 12,063 25.15% | 9,639 26.00% | ||||||||
Cost of revenue | 20,892 | 25,049 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (8,828) | (15,410) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | 2,401 | |||||||||
Tax Rate | ||||||||||
NOPAT | (8,828) | (17,810) | ||||||||
Net income | (14,094) -24.46% | (18,658) -35.95% | ||||||||
Dividends | (18) | (947) | ||||||||
Dividend yield | 0.14% | 23.51% | ||||||||
Proceeds from repurchase of equity | 119 | (883) | ||||||||
BB yield | -0.90% | 21.93% | ||||||||
| Debt | ||||||||||
Debt current | 12,094 | 5,110 | ||||||||
Long-term debt | 13,171 | 16,158 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,436 | 759 | ||||||||
Net debt | 24,329 | 20,601 | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | (6,694) | (13,548) | ||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | 6,742 | 2,002 | ||||||||
FCF | (5,260) | (14,666) | ||||||||
| Balance | ||||||||||
Cash | 786 | 570 | ||||||||
Long term investments | 150 | 96 | ||||||||
Excess cash | 333 | 185 | ||||||||
Stockholders' equity | (125,969) | (112,671) | ||||||||
Invested Capital | 121,307 | 111,524 | ||||||||
ROIC | ||||||||||
ROCE | 189.35% | 1,342.89% | ||||||||
| EV | ||||||||||
Common stock shares outstanding | 8,992 | 8,660 | ||||||||
Price | 1.48 218.28% | 0.47 -79.52% | ||||||||
Market cap | 13,308 230.49% | 4,027 -76.58% | ||||||||
EV | 39,126 | 24,628 | ||||||||
EBITDA | (6,655) | (15,404) | ||||||||
EV/EBITDA | ||||||||||
Interest | 5,192 | 2,583 | ||||||||
Interest/NOPBT | ||||||||||